These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 12678237)

  • 1. Validation of a candidate in vitro potency assay for inactivated Newcastle disease vaccines.
    Maas R; Komen M; Oei H; Claassen I
    Dev Biol (Basel); 2002; 111():163-9. PubMed ID: 12678237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigen content of inactivated Newcastle disease oil emulsion vaccines as an in vitro indicator of potency.
    Maas R; van Diepen M; Komen M; Oei H; Claassen I
    Dev Biol (Basel); 2002; 111():313-8. PubMed ID: 12678255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of the inactivating agent on the antigen content of inactivated Newcastle disease vaccines assessed by the in vitro potency test.
    Jagt HJ; Bekkers ML; van Bommel SA; van der Marel P; Schrier CC
    Biologicals; 2010 Jan; 38(1):128-34. PubMed ID: 19716316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation study to evaluate the reproducibility of a candidate in vitro potency assay of newcastle disease vaccines and to establish the suitability of a candidate biological reference preparation.
    Claassen I; Maas R; Oei H; Daas A; Milne C
    Pharmeuropa Bio; 2004 Dec; 2004(1):1-15. PubMed ID: 15659281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The quantitative ELISA for inactivated Newcastle antigen: experience report from an OMCL.
    Motitschke A; Jungbäck C
    Dev Biol (Basel); 2012; 134():55-66. PubMed ID: 22888596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The quantitative ELISA for inactivated Newcastle disease virus antigen: development of the test system and the way to a Ph. Eur in vitro potency test.
    Oei HL
    Dev Biol (Basel); 2012; 134():51-3. PubMed ID: 22888595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility study to evaluate the correlation between results of a candidate in vitro assay and established in vivo assays for potency determination of Newcastle disease vaccines.
    Claassen I; Maas R; Daas A; Milne C
    Pharmeuropa Bio; 2003 Jul; 2003(1):51-66. PubMed ID: 14563308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigenic differences among Newcastle disease virus strains of different genotypes used in vaccine formulation affect viral shedding after a virulent challenge.
    Miller PJ; King DJ; Afonso CL; Suarez DL
    Vaccine; 2007 Oct; 25(41):7238-46. PubMed ID: 17719150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of inactivated Newcastle disease viral vaccines containing different emulsion adjuvants.
    Brugh M; Stone HD; Lupton HW
    Am J Vet Res; 1983 Jan; 44(1):72-5. PubMed ID: 6824228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study on immune efficacy of Newcastle disease chitosan microsphere vaccine].
    Zhai RL; Xu HY; Wang YL; Qin ZM; Jiang SJ
    Wei Sheng Wu Xue Bao; 2007 Aug; 47(4):692-6. PubMed ID: 17944374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control of Newcastle disease by vaccination.
    Senne DA; King DJ; Kapczynski DR
    Dev Biol (Basel); 2004; 119():165-70. PubMed ID: 15742628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection of chickens against overt clinical disease and determination of viral shedding following vaccination with commercially available Newcastle disease virus vaccines upon challenge with highly virulent virus from the California 2002 exotic Newcastle disease outbreak.
    Kapczynski DR; King DJ
    Vaccine; 2005 May; 23(26):3424-33. PubMed ID: 15837366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigen quantification as in vitro alternative for potency testing of inactivated viral poultry vaccines.
    Maas RA; de Winter MP; Venema S; Oei HL; Claassen IJ
    Vet Q; 2000 Oct; 22(4):223-7. PubMed ID: 11087135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newcastle disease oil emulsion vaccines prepared with animal, vegetable, and synthetic oils.
    Stone HD
    Avian Dis; 1997; 41(3):591-7. PubMed ID: 9356704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Production and trials of inactivated vaccines in oil excipient against Newcastle disease in Ethiopia].
    Thiaucourt F
    Rev Elev Med Vet Pays Trop; 1988; 41(3):229-33. PubMed ID: 3201019
    [No Abstract]   [Full Text] [Related]  

  • 16. Improved protection from velogenic Newcastle disease virus challenge following multiple immunizations with plasmid DNA encoding for F and HN genes.
    Loke CF; Omar AR; Raha AR; Yusoff K
    Vet Immunol Immunopathol; 2005 Jul; 106(3-4):259-67. PubMed ID: 15963824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A vaccine candidate of attenuated genotype VII Newcastle disease virus generated by reverse genetics.
    Hu S; Ma H; Wu Y; Liu W; Wang X; Liu Y; Liu X
    Vaccine; 2009 Feb; 27(6):904-10. PubMed ID: 19095026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SEPPIC vaccine adjuvants for poultry.
    Dupuis L; Ascarateil S; Aucouturier J; Ganne V
    Ann N Y Acad Sci; 2006 Oct; 1081():202-5. PubMed ID: 17135512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statistical evaluation of numbers of animals to be used in vaccine potency testing: a practical approach.
    Akkermans AM; Hendriksen CF
    Dev Biol Stand; 1999; 101():255-60. PubMed ID: 10566799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction, expression and immunoassay detection of recombinant plasmid encoding fusion protein of Roman chicken complement C3d and Newcastle disease virus F gene.
    Liu D; Niu ZX
    Scand J Immunol; 2008 Dec; 68(6):598-606. PubMed ID: 19055698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.